Current Issue February 2012, Vol. 48, No. 3

Issue Highlights

Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
January 2012 (Vol. 48 | No. 2 | Pages 218-225)
Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori, Wim H. Kruit, Jeremy Marsden, Cornelis J. Punt, Mario Santinami, François Salès, Dirk Schadendorf, Poulam Patel, Reinhard Dummer, Caroline Robert, Ulrich Keilholz, Antoine Yver, Alan Spatz
Targeted agents: How to select the winners in preclinical and early clinical studies?
January 2012 (Vol. 48 | No. 2 | Pages 170-178)
Rachel Goodwin, Giuseppe Giaccone, Hilary Calvert, Marinus Lobbezoo, Elizabeth A. Eisenhauer
The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials
January 2012 (Vol. 48 | No. 2 | Pages 187-195)
Tingting Yan, Wenjin Yin, Qiong Zhou, Liheng Zhou, Yiwei Jiang, Yueyao Du, Zhimin Shao, Jinsong Lu

EJC News Focus

WATCH VIDEO

The combination of targeted agents in hormone-sensitive breast cancer may be the way ahead; results from the CLEOPATRA and BOLERO-2 trials, presented at the recent San Antonio Breast Cancer Symposium (Dec 6-10, 2011), suggest that some combinations may dramatically increase progression-free survival.

Also at the meeting, several studies reported on the role of bisphosphonates in the adjuvant setting, which may resolve previous confusion about which women will benefit.

In this month's EJC News Focus, Rob Coleman (University of Sheffield, UK), who was at the meeting, discusses the implications of the new data with Helen Saul.

Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size
27 January 2012
M. Mauer, L. Collette, J. Bogaerts, European Organisation for Research and Treatment of Cancer (EORTC) Statistics Department
Abstract: Given the high failure rates and the increased costs of Phase III trials in oncology and the recent explosion of targeted agents, researchers are looking for better design strategies to try ...
Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitiser ZnPcS2P2: ROS production, apoptosis, cell cycle arrest
24 January 2012
Jingwei Shao, Jinping Xue, Yongchao Dai, Hong Liu, Lee Jia, Naisheng Chen, Jinling Huang
Abstract: Photodynamic therapy (PDT) has been accepted as an alternative treatment for cancer. The rationale for the development of PDT for cancer is that target specificity can be achieved by control...
Quantifying heterogeneity in human tumours using MRI and PET
24 January 2012
Marie-Claude Asselin, James P.B. O’Connor, Ronald Boellaard, Neil A. Thacker, Alan Jackson
Abstract: Most tumours, even those of the same histological type and grade, demonstrate considerable biological heterogeneity. Variations in genomic subtype, growth factor expression and local microen...
Radiomics: Extracting more information from medical images using advanced feature analysis
18 January 2012
Philippe Lambin, Emmanuel Rios-Velazquez, Ralph Leijenaar, Sara Carvalho, Ruud G.P.M. van Stiphout, Patrick Granton, Catharina M.L. Zegers, Robert Gillies, Ronald Boellard, André Dekker, Hugo J.W.L. Aerts
Abstract: Solid cancers are spatially and temporally heterogeneous. This limits the use of invasive biopsy based molecular assays but gives huge potential for medical imaging, which has the ability to...
The antitumour activities induced by pegylated liposomal cytochalasin D in murine models
18 January 2012
Feng-ying Huang, Wen-li Mei, Yue-nan Li, Guang-hong Tan, Hao-fu Dai, Jun-li Guo, Hua Wang, Yong-hao Huang, Huan-ge Zhao, Song-lin Zhou, Ling Li, Ying-ying Lin
Abstract: Cytochalasin D targets actin and is ubiquitous in eukaryotic cells. When cytochalasin D is used as a cytotoxic agent in cancer therapy, it causes significant side effects. To prevent this, c...

View More Articles in Press...

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
January 2011 (Vol. 47 | No. 1 | Pages 8-32)
M.S. Aapro, J. Bohlius, D.A. Cameron, Lissandra Dal Lago, J. Peter Donnelly, N. Kearney, G.H. Lyman, R. Pettengell, V.C. Tjan-Heijnen, J. Walewski, Damien C. Weber, C. Zielinski
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer
June 2011 (Vol. 47 | No. 9 | Pages 1343-1354)
Barbara-Ann Adelstein, Timothy A. Dobbins, Carole A. Harris, Ian C. Marschner, Robyn L. Ward
New drugs in melanoma: It’s a whole new world
September 2011 (Vol. 47 | No. 14 | Pages 2150-2157)
Alexander M.M. Eggermont, Caroline Robert
Preoperative MRI and surgical management in patients with nonpalpable breast cancer: The MONET – Randomised controlled trial
April 2011 (Vol. 47 | No. 6 | Pages 879-886)
N.H.G.M. Peters, S. van Esser, M.A.A.J. van den Bosch, R.K. Storm, P.W. Plaisier, T. van Dalen, S.C.E. Diepstraten, T. Weits, P.J. Westenend, G. Stapper, M.A. Fernandez-Gallardo, I.H.M. Borel Rinkes, R. van Hillegersberg, W.P.Th.M. Mali, P.H.M. Peeters
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
November 2011 (Vol. 47 | No. 17 | Pages 2603-2606)
A. Becker, L. Crombag, D.A.M. Heideman, F.B. Thunnissen, A.W. van Wijk, P.E. Postmus, E.F. Smit

Most Read lists are compiled every quarter.

On the Cover

New Issue Alert

Free Trial Issue

Visit EJC Supplements

Read EJC News

EJC EUROFILE: A second chance to influence the Clinical Trials Directive

EJC INTERVIEW: Elderly breast cancer patients 'risk treatment discrimination'

New: Hormone Receptor Positive Breast Cancer Resource Centre

For all the latest research on Hormone Receptor Positive Breast Cancer, including original research articles and video interviews with leading researchers, visit our new resource centre at www.ejcancer-breast.com, edited by Professor Robert E. Coleman.

Access this journal onSciVerse ScienceDirect

EJC iPad app launch video - September 2011

EJC iPad App is now available to our readers. Download from iTunes now!

About the Journal

European Journal of Cancer is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), and on cancer epidemiology and prevention.

More